AI is rewriting biology's rulebook — and the smartest money is paying attention. Vijay Pande, who oversaw ~$4B in biotech investments at a16z, just made a bold pivot: a smaller, AI-native fund betting that biology is crossing a historic threshold — from *discovery* science to *engineering* science. That's the difference between stumbling upon cures and designing them on demand. His key insight? Open, shared datasets — not proprietary data moats — will be the real unlock for AI in medicine. Clinical trials remain brutally expensive, but if AI can compress the path to the clinic, the economics of biotech change forever. This isn't just venture capital philosophy. It's a signal about where the next wave of breakthroughs — and returns — may come from. #AIinMedicine #Biotech #DrugDiscovery #HealthcareAI #BiologyEngineering --- Companies in this space: Recursion Pharmaceuticals ($RXRX, NASDAQ), Tempus AI ($TEM, NASDAQ), Alphabet/DeepMind ($GOOGL, NASDAQ)